Table 1. Patient Demographic and Clinical Characteristics and Tumor Characteristics of FNA Biopsy Specimens From Patients in the Validation Cohort Prior to Neoadjuvant Therapy (n = 80).
| Characteristic | No. (%) | P value | |
|---|---|---|---|
| MMP-7 negative (n = 34) | MMP-7 positive (n = 46) | ||
| Age, median (IQR), y | 62.8 (54.4-72.4) | 68.3 (61.3-73.2) | .26 |
| Sex | |||
| Female | 19 (55.9) | 21 (45.7) | .49 |
| Male | 15 (44.1) | 25 (54.3) | |
| Race and ethnicity | |||
| Black | 3 (8.8) | 6 (13.0) | .72 |
| White | 31 (91.2) | 40 (87.0) | |
| Type of neoadjuvant | |||
| 5-Fluorouracil based | 23 (67.6) | 33 (71.7) | .71 |
| Gemcitabine based | 9 (26.5) | 9 (19.6) | |
| Other | 2 (5.9) | 4 (8.7) | |
| Chemoradiotherapy | 28 (82.4) | 32 (69.6) | .29 |
| Chemotherapy alone | 7 (20.6) | 14 (30.4) | |
| Duration of neoadjuvant therapy, median (IQR), mo | 3.6 (3.2-4.5) | 3.9 (2.2-5.1) | .26 |
| CA 19-9, median (IQR), U/mLa | 111 (19.4-362.2) | 256 (29.7-884.5) | .36 |
| Tumor size (largest measurement), median (IQR), cm | 3.7 (2.7-4.7) | 3.6 (2.5-4.4) | .97 |
| Vascular involvement | 32 (94.1) | 41 (89.1) | .71 |
| Tumor located in pancreas head/neck region | 26 (76.5) | 25 (54.3) | .07 |
| Pathologic T stage | |||
| pT0 | 7 (20.6) | 0 | .001 |
| pT1 | 15 (44.1) | 11 (23.9) | |
| pT2 | 7 (20.6) | 17 (37.0) | |
| pT3 | 5 (14.7) | 11 (23.9) | |
| pT4 | 0 | 7 (15.2) | |
| Pathologic N stage | |||
| pN0 | 26 (76.5) | 23 (50.0) | .04 |
| pN1 | 7 (20.6) | 17 (37.0) | |
| pN2 | 1 (2.9) | 6 (13.0) | |
| Grade | |||
| Well differentiated | 4 (11.8) | 2 (4.3) | .37 |
| Moderately differentiated | 19 (55.9) | 31 (67.4) | |
| Poorly differentiated | 11 (32.4) | 13 (28.3) | |
| Lymphovascular invasion | 5 (14.7) | 15 (32.6) | .07 |
| Perineural invasion | 10 (29.4) | 33 (71.7) | .001 |
| Margin class of R0b | 31 (91.2) | 40 (87.0) | .72 |
| Adjuvant chemotherapy | 20 (58.8) | 33 (71.7) | .24 |
| Pathologic response (CAP score)c | |||
| 0 | 8 (23.5) | 0 | .001 |
| 1 | 22 (64.7) | 12 (26.1) | |
| 2 | 1 (2.9) | 12 (26.1) | |
| 3 | 3 (8.8) | 22 (47.8) | |
Abbreviations: CA 19-9, cancer antigen 19-9; CAP, College of American Pathologists; FNA, fine-needle aspiration; MMP-7, matrix metalloproteinase 7.
a
Normal, 0 to 37 U/mL.
b
R0 corresponds to a goal of resection for cure or complete remission.
c
CAP score of 0 indicates complete response; 1, marked response; 2, partial response; and 3, poor or no response.